Amarin Corp Plc (AMRN)

[Tatsumaki]

It doenst "suggest" anything. It plainly states if a drug or indication is developed and approved overseas, China deducts the time from that overseas approval from the exclusivity window in China. If you want exclusivity in China, develop the drug in China for 6 years, or run studies in China for a new indication for 3 (like Mochida is doing with Sumitomo... running trials in China...).

but suppose a competitor could develop a generic using data from US generics rather than Amarin directly.

Generics dont generate data on their drugs/indications. They copy existing approved formulations/indications and use the trials the developer ran to first approve the drug.